WO 2005/049629

5

PCT/EP2004/012279

1

## Process for preparing bisphospholane ligands

The present invention is directed at a process for the preparation of bidentate ligands based on bisphospholanes. In particular, the invention relates to the preparation of enantiomerically enriched compounds of the general formula (I):

Enantiomerically enriched ligands are used in asymmetric synthesis or asymmetric catalysis. The important thing here is that the electronic and stereochemical properties of the ligand are optimally matched to the respective catalysis problem. An important aspect of the success of this class of compounds is believed to be the creation of an asymmetric environment around the metal centre due to these ligand systems. To utilize such an environment for effective transfer of the chirality, it is advantageous to control the flexibility of the ligand system as inherent limitation of the asymmetric induction.

Within the class of phosphorus-containing ligands, cyclic phosphines, in particular phospholanes, have attained particular importance. Bidentate, chiral phospholanes are, for example, the DuPhos and BPE ligands used in asymmetric catalysis. In the ideal case, these provide a chiral ligand framework which can be modified in a variety of ways and can be varied within a broad range in terms of its steric and electronic properties.

5

DE10309356 describes concrete ligand systems and a route for preparing them. The synthetic route presented there starts out from phenylphosphine which is converted into a dimetal phenolphosphine by deprotonation with a strong base before the reaction to form the phospholane is carried out.

EP528865 describes the preparation of phospholanes starting from dilithiophenylphosphine and a bifunctional alkylation reagent. The preparation of the dilithiophenylphosphine is not mentioned.

10 EP1028967, JOC 2003, 68, 1701-1707 and Org. Lett. 2003, 5, 1273-75, present preparations of enantiomerically enriched phospholanes. Here too, the conversion into the phospholane is brought about using phenolphosphine or a lithiated bistrimethylsilylphosphide.

15 It was an object of the present invention to provide a further process for preparing the abovementioned phospholanes and enantiomerically enriched ligands. In particular, the process should be economical on an industrial scale from both economic and ecological points of view. Very particular value should be attached to a process which starts out from materials which are readily available commercially and uses reagents which can be handled relatively unproblematically.

Such a process is proposed in the claims. Claim 1 describes a process for preparing the desired ligand systems. The dependent subordinate Caims 2 to 13 are directed at preferred embodiments of the process of the invention.

Carrying out a process for preparing enantiomerically enriched compounds of the general formula (I),

where f

\* indicates a stereogenic centre,

R1 and R4 are each, independently of one another

 $(C_1-C_8)-alkyl$ ,  $HO-(C_1-C_8)-alkyl$ ,  $(C_1-C_8)-alkoxy$ ,

5  $(C_2-C_8)$ -alkoxyalkyl,  $(C_6-C_{18})$ -aryl,  $(C_7-C_{19})$ -aralkyl,

 $(C_1-C_8)$  -alkyl- $(C_6-C_{18})$  -aryl,  $(C_3-C_8)$  -cycloalkyl,

 $(C_1-C_8)$  -alkyl- $(C_3-C_8)$ -cycloalkyl,

 $(C_3-C_8)$ -cycloalkyl- $(C_1-C_8)$ -alkyl,

 ${\ensuremath{\mbox{R}}}^2$  and  ${\ensuremath{\mbox{R}}}^3$  are each, independently of one another, H,

10  $(C_1-C_8)$ -alkyl, HO- $(C_1-C_8)$ -alkyl,  $(C_1-C_8)$ -alkoxy,

 $(C_2-C_8)$ -alkoxyalkyl,  $(C_6-C_{18})$ -aryl,  $(C_7-C_{19})$ -aralkyl,

 $(C_1-C_8)-alkyl-(C_6-C_{18})-aryl, (C_3-C_8)-cycloalkyl,$ 

 $(C_1-C_8)$  -alkyl- $(C_3-C_8)$ -cycloalkyl,

 $(C_3-C_8)$ -cycloalkyl- $(C_1-C_8)$ -alkyl,

15 A is a  $C_2$  bridge in which two carbon atoms have  $sp^2$  hybridization, starting from compounds of the general formula (II),

where

R1 to R4 can be as defined above,

20 M is an alkali metal or a trimethylsilyl group, and reacting these with compounds of the general formula (III),

$$X-A-X$$
 (III)

25 where

A is as defined above and the radicals X are each, independently of one another, a nucleofugic leaving group, and preparing the compounds of the general formula (II) by reacting compounds of the

30 general formula (IV),

4

$$R^2$$
 $*$ 
 $Y$ 
 $R^3$ 
 $*$ 
 $Y$ 
 $R^4$ 
(IV)

where

R<sup>1</sup> to R<sup>4</sup> are as defined above and
the radicals Y are each, independently of one another, a
nucleofugic leaving group,
with compounds of the general formula (V),

$$M_2P-Aryl$$
 (V)

10

15

where

M is an alkali metal and Aryl is a  $(C_6-C_{18})$ -aryl or  $((C_1-C_8)$ -alkyl)<sub>1-3</sub>- $(C_6-C_{18})$ -aryl radical, and subsequently with an alkali metal and additionally, if appropriate, with trimethylsilyl chloride, with the compounds of the formula (V) being obtained by reaction of compounds of the general formula (VI),

20

where

Aryl is as defined above,
with an alkali metal, enables the ligand systems in
question to be obtained simply and particularly

25 advantageously according to the invention. It was
particularly suprising that the procedure described
achieves a relatively good increase in yield, which was not
to have been expected from the prior art.

The process described above is preferably applied to compounds in which A is a radical from the group consisting of

where

5

R is H,  $(C_1-C_8)$ -alkyl,  $(C_6-C_{18})$ -aryl,  $(C_7-C_{19})$ -aralkyl,  $(C_1-C_8)$ -alkyl- $(C_6-C_{18})$ -aryl,  $(C_3-C_8)$ -cycloalkyl,  $(C_1-C_8)$ -alkyl- $(C_3-C_8)$ -cycloalkyl,

- 10 (C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl-(C<sub>1</sub>-C<sub>8</sub>)-alkyl, and Q is O, NH, NR. Q in these formulae is particularly preferably oxygen or NR, with R being able to be(C<sub>1</sub>-C<sub>8</sub>)-alkyl, (C<sub>6</sub>-C<sub>18</sub>)-aryl, benzyl. Especially preferred radicals R are methyl, ethyl, propyl, isopropyl, tert-butyl, phenyl, naphthyl, fluorenyl, benzyl.
- Preference is likewise given to using compounds of the formula (IV) in which  $R^2$  and  $R^3$  are each H and  $R^4$  are each, independently of one another,  $(C_1-C_8)$ -alkyl,  $(C_2-C_8)$ -alkoxyalkyl.
- Preference is also given to using compounds of the general formula (III) or (IV) in which X or Y is selected from the group consisting of halogen, Otos (p-toluenesulfonate), OMes (methylsulfonate), triflate (trifluoroacetate), p-nitrobenzenesulfonate (nosylate, ONs) in the process of the invention.

Particular preference is likewise given to using compounds of the general formula (VII) or (VIII), for compounds of general formular (IV)

5

25

30

where

the radicals Y are selected independently from the group consisting of halogen, OTos, OMes, triflate, nosylate,  $\mathbb{R}^1$  and  $\mathbb{R}^4$  are each, independently of one another,

10  $(C_1-C_8)$ -alkyl,  $HO-(C_1-C_8)$ -alkyl,  $(C_2-C_8)$ -alkoxyalkyl,  $(C_6-C_{18})$ -aryl,  $(C_7-C_{19})$ -aralkyl,  $(C_1-C_8)$ -alkyl- $(C_6-C_{18})$ -aryl,  $(C_3-C_8)$ -cycloalkyl,  $(C_1-C_8)$ -alkyl- $(C_3-C_8)$ -cycloalkyl,  $(C_3-C_8)$ -cycloalkyl- $(C_1-C_8)$ -alkyl,

the radicals R' are each, independently of one another,

15 H,  $(C_1-C_8)$ -alkyl,  $HO-(C_1-C_8)$ -alkyl,  $(C_6-C_{18})$ -aryl,  $(C_7-C_{19})$ -aralkyl,  $(C_1-C_8)$ -alkyl- $(C_6-C_{18})$ -aryl,  $(C_3-C_8)$ -cycloalkyl,  $(C_1-C_8)$ -alkyl- $(C_3-C_8)$ -cycloalkyl,  $(C_3-C_8)$ -cycloalkyl- $(C_1-C_8)$ -alkyl.

Very particular preference is given to compounds of the formula (VII) or (VIII) in which R' is H, methyl, ethyl, propyl, isopropyl, tert-butyl, phenyl, and R<sup>1</sup> and R<sup>4</sup> are each methyl, ethyl, propyl, isopropyl, tert-butyl, phenyl.

In principle, all elements of main group 1 of the Periodic Table can be employed as alkali metals. Preference is here given to lithium, sodium and potassium, with lithium being especially preferred as the metal to be used.

The solvents to be used for the individual steps of the process can be selected by a person skilled in the art on the basis of his general technical knowledge. The solvents should be solvents which do not if at all possible, promote

25

30

any secondary reactions and are themselves inert under the reaction conditions. The reaction of compounds of the general formula (VI) with alkali metals is preferably carried out in an aprotic polar solvent. Very particular preference is here given to ethers such as THF, diethyl ether, dioxane, DME or DEE.

The temperature window within which the reaction according to the invention is carried out can likewise be selected freely by a person skilled in the art. Here, a person skilled in the art will be guided by efficiency factors 10 such as space-time yield, energy costs and by-products spectra and set a temperature which helps to ensure an optimal reaction. The reaction of the compound (IV) with the compound (V) is preferably carried out at a temperature of from -50°C to +100°C, more preferably from -30°C to 15 +80°C and particularly preferably from -25°C to +40°C. The reaction of compounds of the general formula (VI) with alkali metals can, on the other hand, be carried out at temperatures of from -25°C to +40°C, preferably from -15°C to +30°C and particularly preferably from -10°C to +10°C. 20

In a further, preferred embodiment of the present process, the reactions of (VI) with alkali metals to form (V) and subsequently with (IV) and also the further reaction of the products obtained to form (III) and finally with (II) to form (I) can be carried out in a single vessel. Thus, the entire reaction can be carried out in a simple fashion as a one-pot synthesis.

The present process thus offers a further very decisive advantage over the synthetic routes disclosed in the prior art. Furthermore, the choice of starting substances means that no strong, difficult-to-handle bases, e.g. alkyllithium compounds, have to be used in the synthesis. As a result, the present route can be carried out on an industrial scale without costly safety equipment and

precautions, which in the final analysis helps make the products cheaper and thus economically more attractive.

The present invention is generally carried out as follows:

In step 1, the compounds of the formula (IV) are prepared as shown by way of example in the following scheme.

The compounds of the general formula (V) are subsequently prepared and are then reacted with the compounds of the formula (IV).

10

After this, the further synthesis after phenyl/lithium/trimethylsilyl exchange can be completed by reaction of the compounds of the formula (III) with those of the formula (II).

X= CI, Br Y= O, NMe

PCT/EP2004/012279

WO 2005/049629

10

15

The overall yield can reach values of > 60%, preferably > 65% and very particularly preferably > 70%, starting from compounds of the formula (VI).

For the purposes of the present invention, (C<sub>1</sub>-C<sub>8</sub>)-alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl or octyl, including all bonding isomers.

The term  $(C_1-C_8)$ -alkoxy refers to  $(C_1-C_8)$ -alkyl radicals which are bound via an oxygen atom to the respective molecule.

The term  $(C_1-C_8)$ -alkoxyalkyl refers to  $(C_1-C_8)$ -alkyl radicals which have an oxygen atom in their chain.

The term  $(C_3-C_8)$ -cycloalkyl encompasses cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl radicals, etc.

For the purposes of the present invention, a  $(C_6-C_{18})$ -aryleradical is an aromatic radical having from 6 to 18 carbon atoms. In particular, such radicals include phenyl, naphthyl, anthryl, phenanthryl, biphenyl radicals.

20 A  $(C_7-C_{19})$ -aralkyl radical is a  $(C_6-C_{18})$ -aryl radical bound via a  $(C_1-C_8)$ -alkyl radical to the molecule.

Nucleofugic leaving groups are, in particular: halogen, Otosyl (OTos), Omesyl (OMes), triflate, nosylate.

Possible halogens (Hal) are chlorine, bromine and iodine.

For the purposes of the invention, the term enantiomerically enriched means that the proportion of one enantiomer in the mixture with its opposite enantiomer is in a range from >50% and <100%.

The structures shown encompass all possible diastereomers and the enantiomers (R, S form) coming under the respective diastereomer.

The references cited are hereby incorporated by reference into the disclosure of the present invention.

WO 2005/049629 PCT/EP2004/012279

11

#### Examples:

The following examples serve to illustrate the invention. They do not in any way constitute a restriction.

Example 1: (2S,5S)-2,5-Hexanediol bismesylate

#### 5 Variant 1:

60g of (2S,5S)-2,5-hexanediol are dissolved in 400ml of dichloromethane and 177 ml of triethylamine and the solution is cooled to 0°C. The methanesulfonyl chloride is added dropwise as a solution in 50 ml of dichloromethane, with the temperature being kept below 30°C. The reaction solution is stirred at room temperature for 60 minutes and subsequently hydrolyzed with 200 ml of water. The phases are separated and the aqueous phase is extracted once with dichloromethane. The organic phase is washed with saturated sodium chloride solution, dried and the solvent is removed under reduced pressure.

Yield: 138.5g; 99%

#### Variant 2:

120g of (2S,5S)-2,5-hexanediol are suspended in 450 ml of toluene and 353.5 ml of triethylamine and the mixture is cooled to 5°C. A solution of 255.9 ml of methanesulfonyl chloride in 50 ml of toluene is added dropwise to this suspension, with the temperature being kept below 30°C. The reaction solution is stirred at room temperature for 1 hour and subsequently hydrolyzed with 250 ml of water. The phases are separated and the aqueous phase is extracted once with toluene. The organic phase is washed with saturated sodium chloride solution and subsequently dried over magnesium sulfate. The solvent is removed under reduced pressure.

Yield: 256.7g; 92%

Example 2: (2R,5R)-2,5-Dimethyl-1-phenylphospholane Variant 1:

44.4 g of lithium are suspended in 400 ml of THF and the 5 mixture is cooled to 0°C. 143.2 g of dichlorophenylphosphine (dissolved in 200 ml of THF) are slowly added dropwise to this reaction mixture, with the temperature being kept below 30°C. The orange suspension is stirred for 1 hour and the THF is subsequently removed 10 under reduced pressure. The residue is taken up in 600 ml of dimethoxyethane and refluxed for 5 hours. After cooling to room temperature, the suspension is transferred to a further reaction vessel, with the residual lithium remaining in the first vessel. The suspension is cooled to 15 -20°C and 195 g of (2S,5S)-2,5-hexanediol bismesylate (dissolved in 200 ml of toluene) are subsequently added, with the temperature being kept below 5°C. The reaction mixture is stirred at room temperature for a further 8 hours and the solvent is subsequently removed under 20 reduced pressure. The residue is taken up in 500 ml of heptane, the mixture is filtered and the solid is washed twice with 300 ml each time of heptane. The heptane is removed under reduced pressure and the crude product is subsequently distilled (87-89°C / 1 mbar) 25

Yield: 97.1 g; 71%

1H-NMR (C6D6): $\delta = 0.70$  (dd 3H), 1.11-1.30 (m, 2H), 1.20 (dd, 3H), 1.65 (m 1H), 2.00-2.45 (m, 3H), 7.50-7.30 (5H) ppm.

30 31P-NMR (C6D6): $\delta = 11.1$  ppm.

## Variant 2: (comparison)

375 ml of methyllithium (1.6 M in ether) are added at -20°C to a solution of 32 g of phenylphosphine in 300 ml of THF. After the addition, the solution is warmed to room

5 temperature and stirred for 1 hour. 72.5 g of (2s,5s)-2,5-hexanediol bismesylate are dissolved in 75 ml of THF and added to the reaction solution at -20°C. The reaction mixture is warmed to room temperature and stirred for 16 hours. The solvent is subsequently removed under reduced pressure and the residue is taken up in 400 ml of heptane. The reaction mixture is filtered and the residue is washed with 200 ml of heptane. The solvent is removed under reduced pressure and the product is distilled under reduced pressure (72-75°C / 0.5 mbar).

15 Yield: 26.5 g; 52%

### Variant 3: (comparison)

113 ml of butyllithium (1.6 M in hexane) are added at -30°C to a solution of 99 g of phenylphosphine (10% strength in hexane) in 300 ml of THF. After the addition, the solution 20 is warmed to room temperature and stirred for 1 hour. 22.5 g of (25,55)-2,5-hexanediol bismesylate are dissolved in 50 ml of THF and added to the reaction solution at -30°C. The reaction mixture is warmed to room temperature and stirred for 16 hours. The solvent is subsequently 25 removed under reduced pressure and the residue is taken up in 100 ml of heptane. The reaction mixture is filtered and the residue is washed with 100 ml of heptane. The solvent is removed under reduced pressure and the product is distilled under reduced pressure (69-75°C / 0.5 mbar). 30

Yield: 11.65g; 67%

Example 3: (2R,5R)-2,5-Dimethyl-1-trimethylsilylphospholane

1.67 g of lithium are suspended in 60 ml of THF. 7.75 g of
 (2S,5S)-2,5-dimethyl-1-phenylphospholane (dissolved in
 10 ml of THF) are added dropwise at 0°C to this suspension.
5 The reaction solution is stirred at room temperature for
 1 hour and subsequently transferred to a further reaction
 vessel, with the lithium remaining in the first vessel.
 11.2 ml of chlorotrimethylsilane (dissolved in 10 ml of
 THF) are added to this reaction mixture. After 2 hours, the
10 solvent is removed under reduced pressure and the crude
 product is distilled under reduced pressure (80-90°C /
 30mbar).

Yield: 5.15 g; 68%

1H-NMR (CDCl3): $\delta = 0.20$  (d, 9H), 1.25-1.15 (m, 6H), 2.54-1.15 (m, 6H) ppm.

31P-NMR (CDC13): $\delta = -54.4$  ppm.

Example 4: 2,3-Bis[(R,R)-2,5-dimethylphospholanyl]maleic anhydride

4.71g of (2R,5R)-2,5-dimethyl-1-trimethylsilylphospholane (dissolved in 5 ml of ether) are added at 0°C to a solution of 2.09 g of dichloromaleic anhydride in 20 ml of ether and the mixture is stirred at this temperature for a further 15 minutes. After a further 30 minutes at room temperature, the solution is cooled to -78°C. The product crystallizes as brown crystals. The crystals are filtered off and dried under reduced pressure.

Yield: 3.56 g; 87%

1H-NMR (CDC13): $\delta = 1.06$  (dd, 6H), 1.22 (dd, 6H), 2.49-1.25 (m, 12H), 3.32 (m, 2H) ppm.

31P-NMR (CDCl3): $\delta = -2.2$  ppm.

Example 5: {2,3-Bis[(R,R)-2,5-dimethylphospholanyl]maleic anhydride} (cyclooctadiene)rhodium(I) tetrafluoroborate

5 1.90 g of 2,3-bis[(R,R)-2,5-dimethylphospholanyl]maleic anhydride are dissolved in 15 ml of THF and the solution is cooled to -20°C. 2.40 g of [Rh(COD)<sub>2</sub>]BF<sub>4</sub> (suspended in 20 ml of THF) are slowly added to the solution. The solution is warmed to room temperature and stirred for a further 90 minutes. 25 ml of ether are added to the reaction solution and the product is subsequently filtered off. The crystals are washed with 25 ml of ether and dried under reduced pressure.

Yield: 3.51 g; 97%

15 1H-NMR (Aceton-d6): $\delta$  = 1.23 (dd, 6H), 1.57 (dd, 6H), 2.67-1.50 (m 18H), 3.07 (m 2H), 5.15 (s, 2H), 5.85 (s, 2H) ppm. 31P-NMR (Aceton-d6): $\delta$  = 63.8 (d, J =151Hz) ppm.

Example 6: 2,3-Bis[(R,R)-2,5-dimethylphospholanyl]maleimide

- A solution of 4.50 g of (2R,5R)-2,5-dimethyl-1trimethylsilylphospholane (dissolved in 5 ml of THF) is
  added dropwise at 0°C to a solution of 2.70 g of N-methyl2,3-dibromomaleimide in 10 ml of THF and the mixture is
  stirred for a further one hour. The solvent and all
  volatile components are removed under reduced pressure. The
  product is isolated as a red-brown oil.
  - Yield: 3.20g (94%)

1H-NMR (CDCl3): $\delta$  = 1.05 (dd, 6H), 1.22 (dd, 6H), 1.78 (m, 2H), 2.05 (m, 2H), 2.26 (m, 2H), 2.42 (m, 2H), 2.98 (d, 3H), 3.32 (m, 2H) ppm.

31P-NMR (CDC13):

 $\delta = -4.9 \text{ppm}.$ 

#### Claims:

1. Process for preparing enantiomerically enriched compounds of the general formula (I),

5

10

15

where

\* indicates a stereogenic centre,

 ${\bf R}^1$  and  ${\bf R}^4$  are each, independently of one another

 $(C_1-C_8)$ -alkyl, HO- $(C_1-C_8)$ -alkyl,  $(C_1-C_8)$ -alkoxy,

 $(C_2-C_8)$ -alkoxyalkyl,  $(C_6-C_{18})$ -aryl,  $(C_7-C_{19})$ -aralkyl,

 $(C_1-C_8)$  -alkyl- $(C_6-C_{18})$  -aryl,  $(C_3-C_8)$  -cycloalkyl,

 $(C_1-C_8)$  -alkyl- $(C_3-C_8)$ -cycloalkyl,

 $(C_3-C_8)$  -cycloalkyl- $(C_1-C_8)$  -alkyl,

 ${\ensuremath{\mbox{R}}}^2$  and  ${\ensuremath{\mbox{R}}}^3$  are each, independently of one another, H,

 $(C_1-C_8)$ -alkyl, HO- $(C_1-C_8)$ -alkyl,  $(C_1-C_8)$ -alkoxy,

 $(C_2-C_8)$ -alkoxyalkyl,  $(C_6-C_{18})$ -aryl,  $(C_7-C_{19})$ -aralkyl,

 $(C_1-C_8)$  -alkyl- $(C_6-C_{18})$  -aryl,  $(C_3-C_8)$  -cycloalkyl,

 $(C_1-C_8)$  -alkyl- $(C_3-C_8)$ -cycloalkyl,

 $(C_3-C_8)$  -cycloalkyl- $(C_1-C_8)$  -alkyl,

A is a  $C_2$  bridge in which two carbon atoms have  $sp^2$  hybridization,

by reacting compounds of the general formula (II),

where

 $R^1$  to  $R^4$  can be as defined above,

M is an alkali metal or a trimethylsilyl group,

with compounds of the general formula (III),

X-A-X (III)

where

A is as defined above and the radicals X are each, independently of one another, a nucleofugic leaving group, characterized in that the compounds of the general formula (II) are prepared by reacting compounds of the general formula (IV),

10

15

25

5

where

R<sup>1</sup> to R<sup>4</sup> are as defined above and the radicals Y are each, independently of one another, a nucleofugic leaving group, with compounds of the general formula (V),

$$M_2P-Aryl$$
 (V)

20 where

M is an alkali metal and Aryl is a  $(C_6-C_{18})$ -aryl or  $((C_1-C_8)$ -alkyl)<sub>1-3</sub>- $(C_6-C_{18})$ -aryl radical, and subsequently with an alkali metal and, if appropriate, additionally with trimethylsilyl chloride, with the compounds of the formula (V) being obtained by reaction of compounds of the general formula (VI),

$$Hal_2P-Aryl$$
 (VI)

where

5

Aryl is as defined above, with an alkali metal.

2. Process according to Claim 1, characterized in that A is a radical from the group consisting of

- - 3. Process according to Claim 2, characterized in that Q is oxygen or NR, where R can be  $(C_1-C_8)$ -alkyl,  $(C_6-C_{18})$ -aryl, benzyl.
- 20 4. Process according to Claim 3, characterized in that Q is oxygen or NR, where R can be methyl, ethyl, propyl, isopropyl, tert-butyl, phenyl, naphthyl, fluorenyl, benzyl.
- 25 5. Process according to one or more of Claims 1 to 4, characterized in that compounds of the formula (IV) in which R<sup>2</sup> and R<sup>3</sup> are each H and R<sup>1</sup> and R<sup>4</sup> are each, independently of one another, (C<sub>1</sub>-C<sub>8</sub>)-alkyl, HO-(C<sub>1</sub>-C<sub>8</sub>)-alkyl, (C<sub>2</sub>-C<sub>8</sub>)-alkoxyalkyl are used.

- 6. Process according to one or more of Claims 1 to 5, characterized in that compounds of the general formula (III) or (IV) in which X or Y is selected from the group consisting of halogen, OTos, OMes, triflate, nosylate, are used.
- 7. Process according to one or more of Claims 1 to 6, characterized in that compounds of the general formula (VII) or (VIII),

10

where

the radicals Y are selected independently from the group consisting of halogen, OTos, OMes, triflate, nosylate,

 $R^1$  and  $R^4$  are each, independently of one another,  $(C_1-C_8)-\text{alkyl}, \ HO-(C_1-C_8)-\text{alkyl}, \ (C_2-C_8)-\text{alkoxyalkyl},$   $(C_6-C_{18})-\text{aryl}, \ (C_7-C_{19})-\text{aralkyl},$ 

 $(C_1-C_8)$  -alkyl- $(C_6-C_{18})$  -aryl,  $(C_3-C_8)$  -cycloalkyl,

20  $(C_1-C_8)$  -alkyl- $(C_3-C_8)$ -cycloalkyl,

 $(C_3-C_8)$ -cycloalkyl- $(C_1-C_8)$ -alkyl,

the radicals R' are each, independently of one another,

H,  $(C_1-C_8)$ -alkyl,  $HO-(C_1-C_8)$ -alkyl,  $(C_6-C_{18})$ -aryl,  $(C_7-C_{19})$ -aralkyl,  $(C_1-C_8)$ -alkyl- $(C_6-C_{18})$ -aryl,  $(C_3-C_8)$ -cycloalkyl,  $(C_1-C_8)$ -alkyl- $(C_3-C_8)$ -cycloalkyl,  $(C_3-C_8)$ -cycloalkyl- $(C_1-C_8)$ -alkyl, are used for compounds of general formular (IV).

8. Process according to Claim 7,
30 characterized in that
R' is H, methyl, ethyl, propyl, isopropyl, tert-butyl,

phenyl, and  $R^4$  are each methyl, ethyl, propyl, isopropyl, tert-butyl, phenyl.

- Process according to one or more of the Claims 1 to 8,
   characterized in that
   the alkali metal used is lithium.
- 10. Process according to one or more of Claims 1 to 9, characterized in that the reaction of compounds of the general formula (VI) with alkali metals is carried out in an aprotic polar solvent.
- 11. Process according to one or more of Claims 1 to 10, characterized in that the reaction of the compound (IV) with the compound (V) is carried out at a temperature of from -25°C to +40°C.
- 12. Process according to one or more of Claims 1 to 6, characterized in that the reaction of compounds of the general formula (VI) with alkali metals is carried out at temperatures of -10°C to +10°C.
  - 13. Process according to Claim 1, characterized in that the reaction is carried out in a one-pot variant.

Inte nal Application No
PC I7 LP 2004/012279

A. CLA IPC	SSIFIC 7	ATION OF CO7F9/	SUB 650	JECT 58	MA	TTER

According to International Patent Classification (IPC) or to both national classification and IPC

#### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 CO7F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BEILSTEIN Data, CHEM ABS Data

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Υ	WO 03/084971 A (DEGUSSA) 16 October 2003 (2003-10-16)	1-13
Υ .	page 13 - page 15 & DE 103 09 356 A (DEGUSSA) 20 November 2003 (2003-11-20) cited in the application	1-13
Υ	WO 91/17998 A (DU PONT) 28 November 1991 (1991-11-28)	1-13
Υ	Scheme 1 & EP 0 528 865 A (DU PONT) 3 March 1993 (1993-03-03) cited in the application	1-13
A	WO 99/24444 A (CHIROTECH TECHNOLOGY LTD) 20 May 1999 (1999-05-20) page 2 -/	1-13

Further documents are listed in the continuation of box C.	χ Patent family members are listed in annex.
<ul> <li>Special categories of cited documents:</li> <li>A' document defining the general state of the art which is not considered to be of particular relevance</li> <li>E' earlier document but published on or after the international filing date</li> <li>L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</li> <li>O' document referring to an oral disclosure, use, exhibition or other means</li> <li>P' document published prior to the international filing date but later than the priority date claimed</li> </ul>	<ul> <li>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</li> <li>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</li> <li>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</li> <li>"&amp;" document member of the same patent family</li> </ul>
Date of the actual completion of the international search  3 February 2005	Date of mailing of the international search report  18/02/2005
Name and mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2  NL – 2280 HV Rijswijk  Tel. (+31–70) 340–2040, Tx. 31 651 epo nl,  Fax: (+31–70) 340–3016	Authorized officer  Elliott, A

Intel al Application No PCT/EP2004/012279

	- ·	PC17EP200	4/0122/9		
(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT					
alegory °	Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.		
4	& EP 1 028 967 A (CHIROTECH TECHNOLOGY LTD) 23 August 2000 (2000-08-23) cited in the application		1-13		
· ·	PILKINGTON C J ET AL: "Expanding the Family of Phospholane-Based Ligands: 1,2-Bis(2,5-diphenylphospholano)ethane" ORGANIC LETTERS, ACS, WASHINGTON, DC, US, vol. 5, no. 8, 17 April 2003 (2003-04-17), pages 1273-1275, XP002301264 ISSN: 1523-7060 cited in the application Scheme 1		1-13		
	HOLZ JET AL: "Synthesis of a New Chiral Bisphospholane Ligand for the Rh(I)-Catalyzed Enantioselective Hydrogenation of Isomeric beta-Acylamido Acrylates" JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 68, no. 5, 12 February 2003 (2003-02-12), pages 1701-1707, XP002244188 ISSN: 0022-3263 cited in the application Scheme 2		1-13		
<b>Y</b>	BURK M J: "New chiral phospholanes; synthesis, characterization, and use in asymmetric hydrogenation reactions" TETRAHEDRON: ASYMMETRY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 2, no. 7, 1991, pages 569-592, XP002146730 ISSN: 0957-4166 cited in the application Schemes I & III		1-13		
	BLOOMFIELD P R ET AL: "Direct preparation of phenylphosphine dilithium" CHEMISTRY AND INDUSTRY, 25 April 1959 (1959-04-25), pages 541-542, XP009005175 ISSN: 0009-3068 the whole document/		1-13		
	ISSN: 0009-3068	•			

Internal Application No PCT/EP2004/012279

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Jgory		
Y	YAN Y-Y ET AL: "Highly Flexible Synthetic Routes to Functionalized Phospholanes from Carbohydrates" JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 65, 11 February 2000 (2000-02-11), pages 900-906, XP002233658 ISSN: 0022-3263 Scheme 3	1-13
Y	NANDI M ET AL: "Synergistic effects of hemilabile coordination and counterions in homogeneous catalysis: new turnable monophosphine ligands for hydrovinylation reactions"  JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 121, no. 42, 27 October 1999 (1999-10-27), pages 9899-9900, XP002316158 ISSN: 0002-7863 Scheme I	1-13
Υ	BRAUER D J ET AL: "Novel P,N ligands derived from (R)- and (S)-1-phenylethylamine with (2R,5R)-2,5-dimethylphospholanyl groups (DuPHAMIN) for asymmetric catalysis" EUROPEAN JOURNAL OF INORGANIC CHEMISTRY, no. 9, May 2003 (2003-05), pages 1748-1755, XP002316159 ISSN: 1434-1948 Scheme 1, conversion of compound 4 to 5	1-13
Υ	LI W ET AL: "Synthesis of chiral hydroxyl phospholanes from D-mannitol and their use in asymmetric catalytic reactions" JOURNAL OF ORGANIC CHEMISTRY, vol. 65, no. 11, 2 June 2000 (2000-06-02), pages 3489-3496, XP002316160 ISSN: 0022-3263 Scheme I	1-13

.

Inte al Application No
PCT7EP2004/012279

Patent document cited in search report		Publication date		Patent family member(s)		: Publication date
WO 03084971	A -	16-10-2003	BR	0308970	Α	11-01-2005
		:	CA	2481037		16-10-2003
· ·			DE	10309356		20-11-2003
			MO	03084971		16-10-2003
			EP	1490379		29-12-2004
ر شرح اسم مسر مسر مساعد على جاران الساد والمساعد الساد		. سا نت <u>در در در جرنت نے جو در جرنت ہ</u>	HR 	20040904	HZ 	31-12-2004
DE 10309356	Α	20-11-2003	DE BR	10309356 0308970	A1 A	20-11-2003 11-01-2005
			CA	2481037	• •	16-10-2003
			WO	03084971		16-10-2003
			EP	1490379		29-12-2004
		·	HR	20040904		31-12-2004
WO 9117998	Α	28-11-1991	US	5008457	Α	16-04-1991
<del>.</del>			AT	116988	T	15-01-1995
	·		AU-	6527.56		08-09-1994
			AU	7854691		10-12-1991
			CA ·	2082166		18-11-1991
			DE	69106703		23-02-1995 11-05-1995
			DE	69106703 528865	•	20-03-1995
•			DK EP	0528865		
			ES	2067230		16-03-1995
			HK	66995		12-05-1995
			ΗŪ	68116	-	29-05-1995
			JP		•	10-11-1999
			~JP			14-10-1993
				· · · · · · · · · · · · · · · · · · ·		10-11-1992
			SG	9590537 9117998		
			WO US	5177230		
			US.	5206398		27-04-1993
			US	5322956	• -	21-06-1994
EP 0528865	Α	03-03-1993	US	~ 5008457		16-04-1991
			AU	652756		08-09-1994
			CA	2082166	•	18-11-1991
		•	DE	69106703	•	23-02-1995 11-05-1995
			DE EP	69106703 0528865		03-03-1993
			HK	66995		12-05-1995
			HÙ	68116		29-05-1995
			JP	2975683		10-11-1999
			JP	5507078	I	14-10-1993
			NO	924317	•	10-11-1992
			AT	116988		15-01-1995
			AU	7854691		10-12-1991
•			DK	528865		20-03-1995 16-03-1995
	•		ES	2067230 9590537		16-03-1995 01-09-1995
			SG WO	9590537 9117998		28-11-1991
			WO US	5177230		05-01-1993
•			US	5206398		27-04-1993
			US	5322956		21-06-1994
		20-05-1999	AT	206128	T	15-10-2001
WO 9924444	$\boldsymbol{\wedge}$	E0 00 2777				

Inte all Application No
PCT7EP2004/012279

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 9924444	Α		CA	230719	2 A1	20-05-1999
MO 3364444	71		DE	6980184	·	31-10-2001
			DE	6980184		16-05-2002
			EP	102896	7 A1	23-08-2000
			ES	216247	3 T3	16-12-2001
			WO	992444	4 A1	20-05-1999
			JP	200152285	5 T	20-11-2001
			US	654518	3 B1	08-04-2003
EP 1028967	Α	23-08-2000	AT	20612	<del></del> В Т	15-10-2001
			AT	23378	D T	15-03-2003
		·	AU	1041099	9 A	31-05-1999
			AU	105750	D A	29-05-2000
·			CA.	2307192	2 A1	20-05-1999
		•	CA	234714	6 A1	18-05-2000
			DE	6980184	1 D1	31-10-2001
			DE	6980184	1 T2	16-05-2002
		•	DE	6990574		10-04-2003
			DE	6990574		16-12-2004
			EP	102896		23-08-2000
			EP	112706		29-08-2001
			ES	219026		16-07-2003
			WO	002785	-	18-05-2000
•			JP	200152285		20-11-2001
			JP	200252947		10-09-2002
•			US	617224		09-01-2001
·		•	US	654518		08-04-2003
			ES	2162473		16-12-2001
			WO	992444	4 A1	20-05-1999